340B Ceiling-Price Overcharges: How a Manufacturer’s Price Report Reaches the Hospital

340B manufacturer overcharging happens when a drug manufacturer charges a covered entity more than the program’s ceiling price. The overcharge can begin inside the manufacturer’s government pricing department, before a hospital places an order. Leave a qualifying discount out of Best Price, reduce the Medicaid rebate used in the calculation, and the hospital can pay more for the same drug. The person who sees the omitted transaction and the person who sees the hospital invoice may be looking at opposite ends of the same decision.

The injured purchasers are health care providers: eligible hospitals, health centers and clinics serving patients through the 340B program. A price-reporting decision can reach both their purchasing accounts and Medicaid’s rebate accounts. That connection is why the underlying transaction matters as much as the number the manufacturer submitted.

Aventis and GlaxoSmithKline Show Where the Purchaser’s Money Went

Aventis allegedly used private-label agreements to keep discounted sales to Kaiser Permanente out of Best Price. The drugs were Azmacort, Nasacort and Nasacort AQ. According to the Justice Department’s settlement announcement, the agreements simply repackaged the drugs under a new label. The alleged reporting failures ran from 1995 through 2000.

The government alleged that Aventis underpaid Medicaid rebates and overcharged Public Health Service purchasers. In May 2009, the company agreed to a $95.5 million civil settlement. More than $6 million was allocated to Public Health Service entities that had paid inflated prices.

The alleged advantage came from treating a different label as a reason to leave the sale out. The government pricing calculation needed the discounted transaction underneath it.

GlaxoSmithKline’s July 2012 resolution separately included $300 million for alleged false price reporting and Medicaid rebate underpayment. Within that component, $20,235,000 was allocated to certain Public Health Service entities that paid inflated prices. The remaining allocations went to the federal government and states.

How Is the 340B Ceiling Price Calculated?

The 340B ceiling price is average manufacturer price minus the Medicaid unit rebate amount. The federal pricing rule requires a quarterly calculation for each National Drug Code, using the preceding calendar quarter’s average manufacturer price and the smallest unit of measure.

That unit matters when the ceiling reaches a purchase record. A price for a package and a price for its smallest unit need to be put on the same basis before the comparison means anything. The drug, quarter and quantity belong beside the invoice price.

For most brand drugs, the basic rebate is the greater of 23.1% of average manufacturer price or the difference between average manufacturer price and Best Price. An additional rebate applies when the average manufacturer price rises faster than the inflation benchmark. Both rebates enter the ceiling calculation.

A change in average manufacturer price affects both sides of that calculation. Without an inflation rebate, a higher average manufacturer price raises the ceiling when the percentage rebate controls, but leaves it unchanged when the Best Price calculation controls and Best Price stays the same.

The additional inflation rebate can bring the calculated ceiling to zero. Penny pricing supplies the minimum when the calculation falls below that amount, including a zero or negative result.

What Does an Omitted Best Price Discount Do?

The 340B ceiling price effect of omitted Best Price discount information turns on whether the discount changes the unit rebate amount. When the difference between average manufacturer price and Best Price determines the basic rebate and the other inputs stay the same, leaving out a lower qualifying price makes the reported Best Price too high. The basic rebate becomes too small, and the ceiling becomes too high, unless penny pricing already fixes the ceiling.

Best Price reaches beyond the amount printed on a sales invoice. It includes qualifying cash discounts, purchase-conditioned free goods, volume discounts and rebates. Discounts in a bundle must be allocated across the products in the arrangement. Special packaging, labeling or product identifiers do not remove a qualifying price from the calculation.

This is where the contract and the pricing submission meet. A concession given to a favored buyer may change the rebate owed on Medicaid purchases and the ceiling charged to 340B purchasers. Keeping the concession out of the report can keep its benefit away from both.

The Inspector General Found the Missing Sales

Five manufacturers excluded sales to health maintenance organization repackagers from Best Price, according to a March 2003 audit summary from the HHS Office of Inspector General. That exclusion increased the prices charged to 340B entities.

The review covered 11 prescription drugs during the year ended September 30, 1999. The Inspector General estimated that the covered entities had been overcharged $6.1 million, representing 45% of what they paid for those drugs. The providers entitled to the program’s prices paid for the manufacturers’ omissions.

The Inspector General recommended that the Health Resources and Services Administration require the manufacturers to identify each affected entity’s exact overcharge and apply offsets or credits to future purchases. The agency agreed.

For an insider, the revealing comparison is the qualifying sale against its treatment in Best Price. The buyer at the end of the chain may see an invoice that agrees with the manufacturer’s published ceiling. The problem can sit in the calculation of that ceiling itself.

The Evidence Trail From Price Report to Hospital

The evidence connects the underlying sale, the reported price, the calculated rebate and the covered entity’s purchase. Each record answers a different question about how the hospital ended up paying that amount.

Manufacturers submit quarterly average manufacturer price and Best Price information to the Centers for Medicare & Medicaid Services. A senior officer or an authorized delegate certifies the report. The contract, rebate terms and sales records show the concession actually offered. The calculation shows how the company treated it. The submission shows what it told the government.

Those reported prices are confidential. The ceiling-price information system introduced in 2019 gave covered entities access to ceiling prices through restricted access. It did not make the manufacturer’s underlying price reports public. A hospital can know the ceiling offered to it while an analyst inside the manufacturer knows why that ceiling is wrong.

The Health Resources and Services Administration’s manufacturer notices include ceiling-price recalculations, price adjustments, refund notices and changes in National Drug Codes. A notice can identify the affected product or period. The purchasing ledger and refund records show what happened to a particular covered entity. A corrected number in a system and money returned to a purchaser are separate events.

Distribution adds another connection. In a contract-pharmacy arrangement, the covered entity can buy the drug while the manufacturer ships it to the pharmacy. The bill-to and ship-to records can therefore identify different organizations in the same transaction. In a replenishment model, dispensing occurs first, eligibility is determined afterward, and the covered entity then orders at the 340B price to replace the drugs.

The manufacturer remains responsible for delivering the required price through its distribution arrangements. The rule expressly reaches orders through wholesalers, authorized distributors and agents. It treats fees charged directly by a wholesaler separately from the manufacturer’s ceiling price. We connect the price calculation to the actual sale, including who charged each amount and who received it.

The agency’s manufacturer audit process examines policies, internal controls and sales transactions. After an audit requiring repayment, the manufacturer is responsible for identifying and contacting all affected covered entities. A pricing correction reaches its purpose when it reaches those buyers.

A Corrected Ceiling Still Leaves a Refund to Pay

A manufacturer that recalculates a ceiling downward still owes the affected purchaser the difference. The pricing rule includes a failure or refusal to refund or credit a covered entity after revised pricing data produces a lower ceiling. Correcting the report leaves the earlier purchases to be reconciled.

For a new drug, the manufacturer initially estimates the ceiling using wholesale acquisition cost reduced by the appropriate rebate percentage. Average manufacturer price should become available no later than the fourth quarter in which the drug is available for sale. Once the manufacturer determines that its estimate caused an overcharge, it must offer a refund or credit for the difference within 120 days.

The rule also prevents a manufacturer from simply canceling an overcharge against a discount on another drug or transaction. Overcharges and undercharges can be offset when the manufacturer and covered entity agree. The difference matters to someone who sees a refund calculation reduced by credits the buyer never accepted.

A manufacturer that knowingly and intentionally overcharges a covered entity can also face a civil monetary penalty, in addition to repayment.

One Reporting Decision Can Reach Two Programs

A manufacturer pricing insider may see the same concealed concession reduce a Medicaid rebate and inflate a 340B purchase price. Aventis shows that connection in an actual civil settlement. The useful evidence follows the decision across the programs instead of stopping at a corrected spreadsheet.

Knowingly false price reports that deprive Medicaid of rebates can support a False Claims Act case, as the Aventis settlement shows. We trace what the company reported, what it knew and where the money went, including the overcharges left unpaid after a correction. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When You Know What Went Into the Price

If you work in government pricing, manufacturer compliance, distribution or healthcare purchasing, talk to our whistleblower experts about the transaction behind the overcharge. Your knowledge of a concealed discount or an unpaid refund gives us a place to challenge the price the company reported and the money it kept. We bring in pharmaceutical pricing whistleblower lawyers who understand Medicaid rebates and 340B purchases, and stay with you through the case.